Lack of TNF-α Gene Polymorphism (rs1799724) Association with Sustained Virological Response in Iranian Patients with Chronic HCV Infection

  • Published : 2016.08.01


Infection with the hepatitis C virus is a major public health concern which can lead to carcinoma and liver failure. It has been shown that single nucleotide polymorphisms can affect the level of gene activity of tumor necrosis factor (TNF) which has an important role, especially in viral infections which can lead to apaptosis of infected hepatocellular cells. We investigated the impact of three possible genotypes for rs1800629 or A/G single nucleotide polymorphism located downstream of $TNF{\alpha}$ gene promoter in groups of control (n=76) and chronic hepatitis C patients (n=89) focusing on the response to treatment among sensitive and resistant groups. Genomic DNA was extracted from $500{\mu}l$ prepheral whole blood and PCR and RFLP were used to amplify the region of interest and genotyping. With statistical analyzes a p-value <0.05 was considered meaningful. There was no significant difference in distribution of possible three genotypes among healthy individuals and patients (P=0.906, OR=1.194, CI=0.063-22.790). However, the frequency of G allele was higher in patients whereas A allele was more common among healthy individuals (p<0.0001). Further studies with more samples seem to be necessary.


Supported by : Pasteur Institute of Iran


  1. Aman W, Mousa S, Shiha G, et al (2012). Current status and future directions in the management of chronic hepatitis C. Virol J, 2, 9-57.
  2. Andrea S, Antonia D, Clementi M (2012). New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiologica, 35, 387-97.
  3. Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang, et al (2006). Tumor necrosis factor-a promoter polymorphism at position _308 predicts response to combination therapy in hepatitis c virus infection. J Infectious Diseases, 193, 98-101.
  4. Chloe L (2008). Host genetic factors and antiviral immune responses to HCV. Clin Liver Dis, 12, 713-26.
  5. Gane EJ, Stedman CA, Hyland RH, et al (2013). Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med, 368, 34-44.
  6. Gaurav Dogra, Anita Chakravarti, Premashish Kar, et al (2011). Polymorphism of tumor necrosisfactor-a and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-a therapy response. Human Immunol, 72, 935-9.
  7. Guo X, Zhao Z, Xie J, et al (2012). Prediction of response to pegylated-interferon-${\alpha}$ and ribavirin therapy in Chinese patients infected with different Hepatitis C virus genotype. Virol J, 9, 123.
  8. Heba F. Pasha, Mohamed I. Radwan, Hoda A, et al (2013). Cytokines genes polymorphisms in chronic hepatitis C: Impact on susceptibility to infection and response to therapy. Cytokine, 61, 478-84.
  9. Henderson DK (2003). Managing occupational risksfor hepatitis c transmission in the health care setting. Clin Microbiol Rev, 16, 546-68.
  10. Hoofnagle JH (2002). Course and outcome of hepatitis C. Hepatol, 36, 21-9.
  11. Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51.
  12. Khodabandehloo M, Daem Roshani (2014). Prevalence of hepatitis c virus genotypes in iranian patients: a systematic review and meta-analysis. Hepat Mon, 14, 22915.
  13. Klevens RM, Hu DJ, Jiles R, et al (2012). Evolving epidemiology of hepatitis c virus in the united states. Clin Infect Dis, 55, 3-9.
  14. Manns MP, McHutchison JG, Gordon SC, et al (2001). Peginterferon alfa-2b plus ribavirin compared withinterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet, 358, 958-65.
  15. Mirjam B, Joachim A, Isabel A (2013). Host-targeting agents for prevention and treatment of chronic Hepatitis C " Perspectives and challenges, J Hepatol, 58, 375-84.
  16. Mohamed I. Radwan a, Heba F. Pasha b, Rasha H. Mohamed c, et al (2012). Influence of transforming growth factor-b1 and tumor necrosis factor-a genes polymorphisms on the development of cirrhosis and hepatocellular carcinoma in chronic hepatitis C patients. Cytokine, 60, 271-6.
  17. Mohd Hanafiah K, Groeger J, Flaxman AD, et al (2013). Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatol, 57, 1333-42.
  18. Ray Kim W (2010). Global epidemiology and burden of hepatitis C. Microbes Infect, 4, 1219-25.1.
  19. Roba M. Talaat , Ahmed A. Esmail , Reda Elwakil , et al (2011). Tumor necrosis factora, -308 g/a polymorphism 1and risk of hepatocellularcarcinoma in hepatit c virus infect pateints department of tropical medicine. Chinese J Cancer, 31, 29-35.
  20. Sy T, Jamal MM (2006). Epidemiology of Hepatitis C Virus (HCV) Infection. Int J Med, 3, 41-6.
  21. Thio CL (2008). Host genetic factors and antiviralimmune responses to HCV. Clin Liver Dis, 12, 713-26.
  22. Zeisel MB, Lupberger J, Fofana I, et al (2013). TF.Host-targeting agents for prevention and treatment of chronic hepatitis C "Perspectives and challenges. J Hepatol, 58, 375-84.